bluuebunny/crossref_metadata_2025_split huggingface dataset:
Efficacy of a Novel Interim Intervention Technique (IIT) with Retrospective Flash Glucose Monitoring to Improve Glycemic Control
Authors: JAIN AKSHAY B. 
Published: June 2018

Aim: Retrospective blinded flash glucose monitoring system (FGMS) is typically used for 14 days, prior to modification of therapy. We sought to assess the efficacy of a novel approach wherein an interim analysis was done within a week of starting FGMS and utilized to implement therapeutic modifications. The same sensor was reassessed within the following week to see the changes in glycemic control, thereby maximizing utility of a single sensor.
Methods: This is a retrospective analysis of 1consecutive adults with T2DM and HbA1c &gt;7% on pharmacotherapy (oral agents and/or insulin) at a single centre. Patients started on blinded FGMS (Freestyle Libre Pro) were assessed within 1 week to get baseline estimate of glycemic trends. Glucose target range was set at 70-180 mg/dL. Patients kept a food log while on FGMS. Based on the glucose profile reports, dietary and pharmacotherapy changes were made and patients were re-evaluated in the next 7 days to assess the changes due to IIT, while wearing the same sensor. Analysis of pre and post: daily average glucose (DAG), time in target range (TITR), time above target range (TATR) and time below target range (TBTR) was performed.
Results: At baseline, patients had a DAG of 191.3 mg/dL. Average time for interim analysis was 5 days after FGMS initiation. After IIT, the DAG dropped to 137.4 mg/dL, within 14 days (p &lt;0.001). The TATR dropped from 52.1% to 18.3% (p&lt;0.001), with a concurrent decrease in TBTR from 5.7% to 1.5% (p&lt;0.001). Recurrent hypoglycemias were detected in 27 (25%) patients, with average TBTR being 21.1% and TITR being 65.7% on interim analysis. Following IIT, the TBTR reduced to 1.9% (p&lt;0.001) and TITR changed to 86.8% (p&lt;0.001), without increase in TATR in these patients.
Conclusion: Using IIT, changes to patient’s lifestyle and/or pharmacotherapy can be made within a few days of FGMS, with the ability to gauge subsequent changes while still utilizing the same sensor. Significant improvement in glycemic control was achieved using this technique.

Disclosure
A.B. Jain: Speaker's Bureau; Self; Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk Inc., Sanofi.
Early Effects of Sleeve Gastrectomy (SG) on Systemic and Organ-Specific Dietary Fatty Acid Uptake, Postprandial Free Fatty Acids (FFA), and Glucose Metabolism in Type 2 Diabetes (T2D)
Authors: CARREAU ANNE-MARIE , NOLL CHRISTOPHE , GUERIN BRIGITTE , BIERTHO LAURENT , TURCOTTE ERIC E. , TCHERNOF ANDRE , CARPENTIER ANDRÉ 
Published: June 2018

Postprandial dietary fatty acid (FA) biodistribution is impaired in subjects with glucose intolerance, with decreased FA storage in adipose tissues (AT) and increased FA uptake by the myocardium. These abnormalities are improved after 1 year of lifestyle-induced weight loss. Bariatric surgery leads to early metabolic improvements before weight loss, but the early effects on dietary FA metabolism and biodistribution have never been studied. 9 subjects with T2D underwent a 6-hour postprandial metabolic protocol before and 12 days after SG. A liquid meal containing [U-13C]-palmitate and [2H]-glucose was ingested at time 0, with an IV perfusion of [3H]-glucose and [7,7,8,8-2H]-palmitate, allowing quantification of glucose absorption, endogenous glucose production (EGP), lipolysis and dietary FA spillover. A capsule containing a positron-emitting long-chain FA analog (18FTHA) was taken with the meal for the quantification of organ-specific dietary FA uptake using PET/CT (n=6). Twelve days after SG, whole body and hepatic insulin sensitivity increased significantly whereas fasting and postprandial EGP decreased. Postprandial GLP-1, GIP, PYY and glucagon were higher after vs. before SG. Postprandial AUC of FFA (175 vs. 228 mmol/Lx min; p&lt; 0.05) and total FA oxidation were higher (p&lt; 0.02 from 180 min to 360 min), but dietary FA oxidation was reduced after SG (p&lt; 0.002 from 180 min to 360 min). After SG, uptake of dietary FA 6 hours after the meal was reduced in the myocardium (mean SUV 2.07± 0.66 vs. 1.36± 0.44; p=0.06) and was increased in visceral AT (mean SUV 0.24± 0.2 vs. 0.42± 0.2; p=0.03), without changes in other organs.
In conclusion, there is reduced myocardial and increased visceral AT uptake of dietary FA associated with reduced dietary FA oxidation and increased FFA mobilization and oxidation, concomitant with reduced EGP and insulin sensitization in patients with T2D early after SG.

Disclosure
A. Carreau: None. C. Noll: None. B. Guerin: None. L. Biertho: Advisory Panel; Self; Novo Nordisk Inc.. Consultant; Self; Johnson & Johnson Services, Inc., Valeant Pharmaceuticals International, Inc.. E.E. Turcotte: None. A. Tchernof: Research Support; Self; Johnson & Johnson Services, Inc., Medtronic. A. Carpentier: Consultant; Self; UniQure, Janssen Pharmaceuticals, Inc., Siemens. Research Support; Self; Caprion, Merck Sharp & Dohme Corp., GlaxoSmithKline plc., Novartis Pharmaceuticals Corporation, AstraZeneca, Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer Inc., Novo Nordisk Inc., Exelixis, Amgen Inc..
Combining A1C with Glycated Albumin Improves Detection of Abnormal Glucose Tolerance in Nonobese Africans—The Africans in America Study
Authors: KABAKAMBIRA JEAN DAMASCENE , BRIKER SARA M. , BAKER RAFEAL L. , DUBOSE CHRISTOPHER , MABUNDO LILIAN , CHUNG STEPHANIE T. , SACKS DAVID B. , SUMNER ANNE E. 
Published: June 2018

As diabetes prevalence rises in Africa, tests to detect abnormal glucose tolerance (abnl-GT) must be optimized. Recent reports suggest A1C performs well as a diagnostic test for abnl-GT in the OB. In contrast, glycated albumin (GA) contributes to the detection of abnl-GT in the nonobese. To determine if BMI affects sensitivity of A1C and GA in Africans, we evaluated the sensitivity of A1C and GA separately and combined to detect abnl-GT in 88 OB blacks (age 42±10y, BMI 33.4±2.9, range 30.0-42.4) and 232 nonobese blacks (age 38±10y, BMI 25.5±2.6, range 18.2-29.8) who were born in Africa and live in the U.S.A. Abnl-GT was determined by glucose criteria for the OGTT. Thresholds for A1C and GA were defined by the cut-off at their upper quartile (A1C≥5.7%; GA ≥13.97%). Prevalence of abnl-GT in OB and nonobese Africans were: 43% v 35%, P=0.20, resp. In the OB, sensitivities of A1C, GA and the combined tests were: 67%, 29% and 79% resp (Figure A). In the OB, sensitivity of A1C + GA was similar to A1C alone (P=0.13). For the nonobese, sensitivities of A1C, GA and the combined tests were: 35%, 38% and 62% resp (Figure B). Sensitivity increased when the tests were combined because abnl-GT was detected in 22 nonobese Africans not identified by A1C. Patterns were similar by sex and region of Africa. Data from Africans living in the U.S.A suggest detection of abnl-GT in the nonobese is improved by combining A1C with GA.

Disclosure
J. Kabakambira: None. S.M. Briker: None. R.L. Baker: None. C. DuBose: None. L. Mabundo: None. S.T. Chung: None. D.B. Sacks: Other Relationship; Self; Sebia, Trinity Biotech. A.E. Sumner: None.
Serum Total Adiponectin Level Is Associated with Incident Prediabetes in Japanese Workers
Authors: HATA AKIKO , MIYOSHI MASASHI , NAKAO TAKAYUKI , ICHIHARA TAKAKO , TAMURA AYAKO , MINAGAWA TAKAKO , KUWAMURA YUMI , FUNAKI MAKOTO 
Published: June 2018

Emerging evidence suggests that adiponectin secreted into the serum by adipocytes may be involved in the development of type 2 diabetes. In addition, some cross-sectional studies have suggested that adiponectin may be related to PreD (prediabetes). Thus, it is reasonable to expect that adiponectin may play a role in PreD development. However, there are still few prospective cohort studies, which could successfully demonstrate a causative relationship between adiponectin and PreD. The aim of this study was to establish the significance of Adipo (serum total adiponectin level) as a biomarker for PreD in Japanese workers. To this end, we analyzed data in our prospective occupational-based cohort study, which has been conducted since 2008. A total of 551 workers without PreD aged 20-60 years were followed-up (mean follow-up period 4.2 years). The subjects were divided into four categories based on the quartiles of baseline Adipo for each sex (male: &lt; 4.9, 4.9-6.6, 6.7-8.9 and &gt; 8.9 µg/ml, female: &lt; 8.2, 8.2-11.1, 11.2-13.9 and &gt; 13.9 µg/ml). The age- and sex-adjusted incidence of PreD significantly increased with decreasing quartile of Adipo at baseline (P for trend &lt;0.001). In multivariate analyses after adjusting for age, sex, BMI, smoking habit, alcohol intake, regular exercise, HDL cholesterol, triglycerides, family history of diabetes, and hypertension, the hazard ratio of PreD was 1.64 [95% confidence interval: 1.to 2.51, P=0.02] in the second quartile and 1.33 [95% confidence interval: 0.83 to 2.11, P=0.24] in the lowest quartile, when compared with the highest quartile. Furthermore, the risk of PreD was 5% higher (P=0.04) with a per 1 µg/ml decrement of Adipo in the multivariate-adjusted model. These results suggest that decreased Adipo is a risk factor for the incidence of PreD in Japanese workers, which could assign a new role to Adipo as a biomarker for the early stage of glucose homeostasis disorders, besides being a biomarker for the development of diabetes and cardiovascular events.

Disclosure
A. Hata: None. M. Miyoshi: None. T. Nakao: None. T. Ichihara: None. A. Tamura: None. T. Minagawa: None. Y. Kuwamura: None. M. Funaki: Research Support; Self; Otsuka Holdings Co., Ltd., The Knowledge Cluster from the Ministry of Education, Science, and Culture of Japan. Board Member; Self; Mechanogenic C.C..
The Prevalence of Undiagnosed Diabetes Has Not Decreased in Spite of Increased Screening in an Australian Rural Area
Authors: SIMMONS DAVID , GLENISTER KRISTEN , MAGLIANO DIANNA J. , WRIGHT SIAN J. , BOURKE LISA 
Published: June 2018

In the mid-2000s in Australia, national guidelines were introduced to promote diabetes screening in people aged 40+ years. We have tested whether diabetes screening has increased, and the prevalence of undiagnosed diabetes has decreased since the introduction of these guidelines. ’Crossroads’ is a repeat cross-sectional study conducted between 2000-2003 (Crossroads-I) and then 2016-2018 (Crossroads-II) in rural Australia (the Goulburn Valley, Victoria). Households visited were randomly selected, and the same households were then revisited in Crossroads-II, alongside proportionately randomly selected new houses. All adult residents are interviewed face to face by trained research assistants. Questions enquire about diabetes status, occurrence of diabetes screening in last 2 years and primary care utilisation. Randomly selected participants are invited to attend a ’clinic’ including a glucose tolerance test. The Crossroads-I cohort (n=3787) was younger and had a higher proportion of male participants than the Crossroads-II cohort (n=1733) (44 ± 17 vs. 53 ± 19 years p&lt;0.0001, 46% vs. 42% male, p&lt;0.0001). The age standardised prevalence of self-reported diabetes (7.0% vs. 5.4%, p&lt;0.05), and age standardised screening rates (56.5% vs. 49.7%, p&lt;0.05) were higher in Crossroads-II than Crossroads-I. Crude undiagnosed diabetes prevalence was also higher in Crossroads-II than Crossroads-I (17/430 (3.9%) vs. 15/814 (1.8%) p&lt;0.05). Primary care utilisation was higher in Crossroads-II than I (6.4 vs. 4.7 visits in past 12 months, p&lt;0.0001) and waiting times were shorter (3.0 vs. 3.9 days, p&lt;0.0001). We conclude that diabetes screening has increased in this area in association with improved access to primary care, and guideline changes. Despite this, rates of undiagnosed diabetes have also increased in line with the overall prevalence of diabetes. Additional strategies are required to reduce undiagnosed diabetes rates further.

Disclosure
D. Simmons: Speaker's Bureau; Self; Roche Diabetes Care Health and Digital Solutions, AstraZeneca, Novo Nordisk Inc., Medtronic. K. Glenister: None. D.J. Magliano: None. S.J. Wright: None. L. Bourke: None.
To Evaluate Patient Characteristics in Those with Elevated NT-proBNP in Type 2 DM Patients Optimized for Conventional CV Risk Factors on Standard Care for Two Years
Authors: GUPTA VISHAL , TELI VAISHALI 
Published: June 2018

Methodology: Two hundred T2DM patients on standard glucose lowering agents and who may be on lipid and blood pressure lowering agents were followed up for 2 years for improvement in CV risk markers like BMI, HbA1c, systolic blood pressure(S-BP), diastolic BP(D-BP), total cholesterol(TC), HDL, non-HDL, LDL, triglycerides(TG), cholesterol remnant(CR), highly-sensitive CRP(hsCRP), serum creatinine(Cr) and eGFR. T2DM patients with recent history of re-vascularisation or any major surgery were excluded. At the end of 2 years, NT-proBNP was measured as an assessment tool for residual CV risk. Those with higher NT-proBNP(&gt;=125) were identified and patient level characteristics as described above were analysed and compared to patients with NT-proBNP &lt;125. Data was analysed using SPSS version 20, represented as Mean + 2(SD) with 95% CI, descriptive statistics and independent t test was used and p-value of less than 0.was considered statically-significant (Si)&gt;.
Results: Baseline characteristics of patients with elevated NT-pro-BNP were: 40(54.05%) males and 34 (45.9%) females, mean age 63.54 ± 10.61 years, mean age since diagnosis 13.5 ± 7.3 years and mean BMI 29.41 ± 5.32 kg/m2. The mean values at the end of 2 years in patients with elevated NT-proBNP were: HbA1c 6.7 ± 1.13, S-BP 132.24 ± 27.5, D-BP 72.93 ± 17.14, TC 140.22 ± 48.98, LDL 70.57 ± 32.95, TG 131.13 ± 91.37, HDL 38.8 ± 13.02, non-HDL 90.18 ± 37.44, CR 23.11 ± 17.7, Cr 1.01 ± 0.29, eGFR 79.29 ± 25.2, hsCRP 4.09 ± 0.51,. There was Si difference seen with regard to Age(p-0.039), weight(p-0.015), D-BP(p-0.016), non-HDL(p-0.05), Cr(p-0.001), eGFR(0.001) at 2 years in patients with elevated NT proBNP compared to those with normal levels.
Conclusion: Patients with elevated NT-proBNP were older, had greater D-BP, TC, LDL, TG, non HDL, CR, Cr and weight and lower HDL and eGFR compared to patients without elevated NT pro BNP at 2 year.

Disclosure
V. Gupta: None. V. Teli: None.
Activation of Cardiac Mitochondrial Akt Signaling Improved Diabetic Cardiomyopathy and Induced Liver Metabolic Remodeling
Authors: TA ALBERT , CHEN YU-HAN , CHEN YUMAY , LEE HYE-JIN , LIN HUGO YOU-HSIEN , WANG PING H. 
Published: June 2018

Insulin stimulates Akt translocation to cardiac mitochondria, and we have recently shown that inhibition of cardiac mitochondrial Akt led to mitochondria dysfunction and cardiomyopathy. However, it is unknown whether activation of mitochondrial Akt in cardiac muscle can protect against the development of diabetic cardiomyopathy. To this end, we have generated an inducible, heart-specific, transgenic mice harboring a mitochondria-targeting constitutively active Akt (CAMAAKT). After 5 months of high fat-high fructose diet (HFF), the control mice developed myocardial fibrosis and cardiomegaly. In contrast, myocardial fibrosis and cardiomegaly were attenuated in the CAMAAKT mice on HFF. Compared to the control mice, the expression of myocardial BNPa, BNPb, and Myh7 (heart failure genes) were significantly suppressed in the CAMAAKT mice by 80%, 90%, and 80%, respectively (all p&lt;0.01). Col1a1 and Col3a1 expression were reduced in the HFF-CAMAAKT mice, corroborating the reduction of myocardial fibrosis. These data indicated that activation of mitochondrial Akt protected against cardiomyopathy in diet-induced diabetes. In OGTT, fasting glucose level was unchanged but postprandial glucose levels were lower in the CAMAAKT mice. In another heart-specific transgenic mice harboring a mitochondria-targeting dominant negative Akt (CAMDAKT), the glucose curve in OGTT was significantly higher than the control mice. Therefore, mitochondrial Akt signaling in the heart could modulate whole body glucose homeostasis. Interestingly, the diet-induced fatty liver in the CAMAAKT mice was significantly less than the controls, suggesting that cardiac mitochondrial Akt signaling may remotely modulate fat metabolism in the liver.
In summary, activating cardiac mitochondrial Akt protected against diabetic cardiomyopathy, improved glucose tolerance, and attenuated fatty liver in HFF-induced diabetes.

Disclosure
A. Ta: None. Y. Chen: None. Y. Chen: None. H. Lee: None. H. Lin: None. P.H. Wang: None.
Impact of Patient-Centered Factors on Comparative Effectiveness of Initial Therapies in Treatment-Naïve T2D
Authors: TESTA MARCIA A. , TURCHIN ALEXANDER , SU MAXWELL , SIMONSON DONALD C. 
Published: June 2018

The 2017 ADA and AACE consensus statements recommend individualizing A1C targets based on patient-centered demographic, clinical and socio-economic factors, and also starting initial therapy with metformin. We used benchmarking algorithms to predict personalized A1C outcomes and estimate treatment comparative effectiveness among diabetes therapies using electronic health records (EHR) collected from 233,627 primary care adult diabetes patients between 2000 and 2014, with 14,019 qualifying as treatment-naïve prior to or at the first EHR observation. EHR analyses were conducted at Partners HealthCare, an integrated healthcare delivery network in eastern Massachusetts. Initial monotherapy regimens were metformin (MET) 63.5%, sulfonylurea (SU) 12.5%, insulin 7.7%, thiazolidinediones (TZD) 1.5% and all other agents &lt; 1%; combination therapies were 14%. The monotherapy MET and SU subgroup (n=10,466) was 53% female; 64% white, 15% black, 8.5% Hispanic; mean± SD age = 59 ± 13 yrs; A1C = 8.6 ± 1.8%; BMI = 33.2 ± 6.5 kg/m2; and median income = $67,119. Of these, 14.8% failed to reach A1C &lt; 7%, and 9.0% did not reach A1C &lt; 8%, prior to a first change in regimen. Logistic regression and survival models for achieving target A1C adjusting for baseline sex, age, race/ethnicity, income, BMI, hypertension, A1C and eGFR were predictive (p &lt; 0.001). SU had lower odds of reaching A1C &lt; 7% vs. MET [OR (95% CI) = 0.69 (0.59, 0.86); HR = 0.60 (0.57, 0.62)], p &lt; 0.001. In the full sample (n = 14,019), all other regimens also had lower odds of A1C &lt; 7% compared to MET [OR (95% CI): Insulin 0.28 (0.24, 0.33); Combinations 0.32 (0.29, 0.36); DPP-4i 0.35 (0.18, 0.67); Other 0.41 (0.22, 0.75); TZD 0.57 (0.39, 0.82); SU 0.72 (0.62, 0.84)]. Patient-centered factors contributed substantially to the heterogeneity of A1C treatment response as benchmarked against metformin; however, even after adjustment, metformin was more effective as initial therapy in T2D treatment naïve patients compared to all other treatments.

Disclosure
M.A. Testa: Stock/Shareholder; Spouse/Partner; GI Windows, Inc.. Stock/Shareholder; Self; Phase V Technologies, Inc. A. Turchin: Research Support; Self; Sanofi-Aventis. Advisory Panel; Self; Merck Sharp & Dohme Corp., Monarch Medical Technologies. Stock/Shareholder; Self; Brio Systems. Research Support; Self; Eli Lilly and Company. M. Su: None. D.C. Simonson: Advisory Panel; Self; GI Windows, Inc.. Stock/Shareholder; Self; GI Windows, Inc.. Stock/Shareholder; Spouse/Partner; Phase V Technologies, Inc.
Continuous Glucose Monitoring in Youth with Pre-Type 1 Obesity/Pre-Type 2 Diabetes and Cystic Fibrosis
Authors: CHAN CHRISTINE L. , STECK ANDREA , VIGERS TIM B. , PYLE LAURA , DONG FRAN , THURSTON JESSICA , REWERS MARIAN , ZEITLER PHIL , NADEAU KRISTEN J. 
Published: June 2018

Continuous glucose monitoring abnormalities are present in the prediabetic state, but how these abnormalities compare among individuals at risk for different types of diabetes (type 1, type 2, vs. cystic fibrosis related diabetes) is unknown. We compared CGM patterns of three distinct groups of youth at risk for diabetes, all with A1c &lt;6.5%: pre-T1D (multiple islet antibody positive), obese/pre-T2D (BMI ≥85th%Ile), and cystic fibrosis (CF). None were on insulin or other medications affecting glucose metabolism. CGM was obtained for 3-7 days in our observational studies. Pre-T1D youth (A1c range 5.0-6.3%) were randomly matched 1:3 on A1c to the obese/pre-T2D and CF youth. Groups were compared using random effects models for continuous variables. Age, Sex distribution and HbA1c were not different between the groups after matching. The results are shown in the table. Of interest, youth with CF and pre-T1D had greater standard deviation, higher maximum and lower minimum glucoses than obese/pre-T2D youth.
In conclusion, CGM patterns are significantly different in pre-T1D and CF compared to obese/pre-T2D, reflecting differences in pathophysiology among these disease states. Early insulin deficiency appears to manifest as greater glycemic variability—higher SD, greater peaks and lows—in pre-T1D and CF, while insulin resistance leads to increased, but less variable, glucoses in obese/preT2D youth.
*pre-T1D and CF significantly different from pre-T2DCGM measure (sensor glucose) Mean (SE) (mg/dl)Pre-T1D (N=14)Pre-T2D (n=42)CF (n=42)P-valueAverage glucose117 (3)114 (2)111 (2)0.17Standard deviation (SD)26 (2)16 (1)22 (1)&lt;0.0001*Maximum223 (14)162 (5)209 (7)&lt;0.0001*Minimum62 (4)77 (2)62 (2)&lt;0.0001*% time &gt;12037 (5)31 (4)27 (2)0.24% time 14017 (4)12 (3)9 (1)0.23% time &gt;2001.3 (0.7)0.4 (0.2)0.8 (0.2)0.11

Disclosure
C.L. Chan: None. A. Steck: None. T.B. Vigers: None. L. Pyle: None. F. Dong: None. J. Thurston: None. M. Rewers: None. P. Zeitler: Consultant; Self; Daiichi Sankyo Company, Limited, Merck & Co., Inc., Eli Lilly and Company, Takeda Development Center Americas, Inc., Boehringer Ingelheim GmbH. K.J. Nadeau: None.
Study on the Screening and Influence Factors for Prediabetes or Diabetes in Primary Health Care Centers of Shanghai
Authors: YINGLING CHENG 
Published: June 2018

Background: Many studies have reported that diabetes mellitus show the low age tendency. Undiagnosed diabetes patients account for about 25-30% of diabetic patients.
Objective: This study aimed to analyze the epidemiological status and influence factors of prediabetes and diabetes, in order to build screening and intervention system for high-risk population in the primary health care centers.
Methods: A cross-sectional study was conducted. Residents over 35 years old were randomly enrolled from Jun 2016 to Aug 2017 in Electric Health Record (EHR) of Shanghai Minhang District. Data were collected by using questionnaire and physical examination and blood glucose test. Logistic regression was applied to analyze the risk factors for prediabetes and diabetic patients.
Results: A total of 12136 subjects were participated in this screening. Results indicated that 14.54% (n=1765) were diagnosed with diabetes and the prevalence rate in males (17.32%) was significantly higher than in females (12.97%) in each age groups (P&lt; 0.001). Furthermore, 20.69% (n=2511) were diagnosed with prediabetes and males were (23.40%) higher than females (19.16%) (P&lt;0.001). Obesity (BMI≥28)(OR=2.35), family history (OR=1.71), history of cardiovascular disease (OR =1.42), hypertension (OR=1.17), central obesity (OR=1.22), age (OR=1.03), gender (OR=1.31) and sedentary (OR=1.02) were the risk factor for prediabetes or diabetes (p&lt;0.001). In addition, we also found that 54.29% (n= 6589) had over 3 risk factors.
Conclusions: It is concluded that we should pay more attention to population with family history and obesity in the screening of diabetes. Grading management and screening should be carried out in different stages of diabetes. Comprehensive prevention and control should be taken to slow progress in diabetes.

Disclosure
C. Yingling: None.